Bbi-Dsp7888-102Ci- A Phase 1B, Multicenter, Open-Label Study Of Dsp-7888 Dosing Emulsion In Combination With Immune Checkpoint Inhibitors Nivolumab Or Atezolizumab In Adult Subjects With Advanced Solid Tumors
Posted Date: Jul 1, 2019
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Oncology
- Type of Study: Drug
This study is a Phase 1b/2, open label, multicenter study for adult patients with solid tumors that evaluates the safety, tolerability, and identify a recommended intradermal dose of DSP 7888 in combination with Nivolumab or Pembrolizumab
Criteria:
To Be Eligible: Age 18 Or Older, Nonpregnant/Breastfeeding, Life Expectancy >3 Months, No Uncontrolled Current Illness
Keywords:
Tumors, Cancer, Advanced
For More Information:
Uccc Cancer Center
513-584-7698
cancer@uchealth.com